Prevalence, Incidence, and Clinical Relevance of the Reverse Transcriptase V207I Mutation Outside the YMDD Motif of the Hepatitis B Virus Polymerase during Lamivudine Therapy
Authors:
Open Access
- 1 May 2005
- journal article
- case report
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (5) , 2503-2505
Abstract
The reverse transcriptase V207I mutation within the hepatitis B virus (HBV) polymerase is associated with resistance to lamivudine in vitro. The prevalence of this mutation in treatment-naïve patients was 1% (1/96). A follow-up of the patient carrying this mutation prior to treatment revealed no loss of sensitivity of HBV to lamivudine in vivo.Keywords
This publication has 11 references indexed in Scilit:
- Viral features of lamivudine resistant hepatitis B genotypes A and DHepatology, 2004
- Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from SpainEnfermedades Infecciosas y Microbiología Clínica, 2004
- Mechanisms for Inhibition of Hepatitis B Virus Gene Expression and Replication by Hepatitis C Virus Core ProteinJournal of Biological Chemistry, 2003
- Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriersJournal of Hepatology, 2001
- Virologic and Clinical Expressions of Reciprocal Inhibitory Effect of Hepatitis B, C, and Delta Viruses in Patients With Chronic HepatitisHepatology, 2000
- High-Throughput Quantitative Analysis of Hepatitis B Virus DNA in Serum Using the TaqMan Fluorogenic Detection SystemHepatology, 2000
- In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistanceHepatology, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Role of Additional Mutations outside the YMDD Motif of Hepatitis B Virus Polymerase in l(−)SddC (3TC) ResistanceBiochemical Pharmacology, 1998